193 related articles for article (PubMed ID: 21119513)
1. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
2. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
3. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
4. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
5. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
Gray J; Simon G; Bepler G
Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
[TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
7. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
8. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 measurements in clinical oncology.
Reed E
N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
[No Abstract] [Full Text] [Related]
10. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
11. Evolution of therapy decision-making process for advanced non-small cell lung cancer.
Gebbia V; Mancuso G; Lombardi L; Maiello E
Oncology; 2009; 77 Suppl 1():97-102. PubMed ID: 20130437
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
17. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.
Kim B; Lee HJ; Choi HY; Shin Y; Nam S; Seo G; Son DS; Jo J; Kim J; Lee J; Kim J; Kim K; Lee S
Cancer Res; 2007 Aug; 67(15):7431-8. PubMed ID: 17671213
[TBL] [Abstract][Full Text] [Related]
18. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer.
Zalcman G; Bergot E; Creveuil C; Levallet G; Lechapt E
Curr Opin Oncol; 2011 Jan; 23(1):106-11. PubMed ID: 21076302
[TBL] [Abstract][Full Text] [Related]
19. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Azuma K; Komohara Y; Sasada T; Terazaki Y; Ikeda J; Hoshino T; Itoh K; Yamada A; Aizawa H
Cancer Sci; 2007 Sep; 98(9):1336-43. PubMed ID: 17640298
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
